Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cash & Equivalents data on file, last reported at $69.8 million in Q4 2025.

• Quarterly Cash & Equivalents fell 1.63% year-over-year to $69.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.8 million (down 1.63% YoY) and the FY2025 annual result came in at $69.8 million, down 1.63% from the prior year.
• Cash & Equivalents eased to $69.8 million in Q4 2025 per LUNG's latest filing, from $76.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $209.3 million in Q1 2021 and bottomed at $63.3 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $98.3 million (2023), against an average of $108.2 million.
• The widest annual swing landed in 2021, when Cash & Equivalents surged 1188.61%; it then slumped 40.24% in 2022.
• Tracing LUNG's Cash & Equivalents over 5 years: stood at $148.5 million in 2021, then tumbled by 31.48% to $101.7 million in 2022, then retreated by 17.88% to $83.5 million in 2023, then slipped by 15.13% to $70.9 million in 2024, then dropped by 1.63% to $69.8 million in 2025.
• Per Business Quant, the three latest LUNG Cash & Equivalents figures stand at $69.8 million (Q4 2025), $76.5 million (Q3 2025), and $75.5 million (Q2 2025).

Peer Comparison